















Dear Pharmacist,

AstraZeneca would like to notify you of an upcoming change in the appearance of the ATACAND® (candesartan cilexetil) and ATACAND HCT® (candesartan cilexetil-hydrochlorothiazide) tablets. As you can see below, the new tablets will be scored down the middle.

| | Before | After |
|---------------|---|--|
| Atacand 4 mg |  |  |
| Atacand 8 mg |  |  |
| Atacand 16 mg |  |  |
| Atacand 32 mg |  |  |

| | Before | After |
|------------------------|---|--|
| Atacand HCT 16/12.5 mg |  |  |
| Atacand HCT 32/12.5 mg |  |  |

This change is being made to present a unified global tablet image – please note that only the appearance of the ATACAND and ATACAND HCT tablets have changed, in all other respects the tablets are identical to the current version. The change to a scored tablet will be applicable to all tablet strengths.

Please exhaust your existing supply of ATACAND and ATACAND HCT tablets before dispensing the new tablets. It will take time for the tablet changes to be realized in their entirety due to varying stock levels and supply chain velocity. The retail and sample packs will arrive at different times. HUD packs will not receive scored tablets until early 2008.

All ordering information, pricing, NDC numbers, and specifications for ATACAND and ATACAND HCT will remain the same.

Thank you for your continued support of ATACAND and ATACAND HCT.

Please see accompanying full Prescribing Information, including boxed WARNING regarding use in pregnancy.